Sinovac immunizes all patients in bird-flu vaccine trial

By Elaine Rigoli

Tampa, Fla., April 10 - Sinovac Biotech Ltd. announced Monday that all 120 volunteers in the phase 1 clinical trial of its avian influenza vaccine (H5N1) have completed the two-shot regimen of either the vaccine or a placebo.

Ranging in age from 18 to 60 years old, the trial volunteers were thoroughly evaluated and medically documented prior to entering the vaccination program, according to a news release.

The clinical trial was conducted on a zero and 28-day dose immunization schedule, the release said.

Sinovac said it expects to take blood samples from volunteers to analyze the antibody growth and effectiveness of the vaccine.

Sinovac is a Beijing, China-based biopharmaceutical company focused on research, development and commercialization of vaccines designed to combat human infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.